A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).

Trial Profile

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Osimertinib (Primary) ; Savolitinib (Primary) ; Durvalumab; Selumetinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms TATTON
  • Sponsors AstraZeneca
  • Most Recent Events

    • 21 Jul 2017 According to a Chi-Med media release, data from this trial will be presented at a scientific conference in H2 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 31 May 2017 Results of an application of computational strategy to explore pharmacokinetic and drug interaction effects in this study, published in the Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top